Inhibikase Therapeutics (IKT) Misses Q3 EPS by 13c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q3 EPS of ($0.13).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
- HSBC Upgrades Sembcorp Industries (SCI:SP) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
